Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection

@inproceedings{Dousson2018CurrentAF,
  title={Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection},
  author={Cyril B Dousson},
  booktitle={Antiviral chemistry & chemotherapy},
  year={2018}
}
This review describes the current state of discovery of past most important nucleoside and nucleotide prodrugs in the treatment of hepatitis C virus infection as well as future potential drugs currently in discovery or clinical evaluation. I highlight first generation landmark prodrug compounds which have been the foundations of incremental improvements toward the discovery and approval milestone of Sofosbuvir. Sofosbuvir is the first nucleotide prodrug marketed for hepatitis C virus treatment… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients. In: The Liver Meeting, Sixty-second AASLD

M Rodriguez-Torres
  • San Francisco, USA,
  • 2011
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Design, synthesis and antiviral evaluation of 20-C-methyl branched guanosine pronucleotides: the discovery of IDX19368, a potent inhibitor of HCV replication

C Pierra Rouviere
  • 2017

Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs

Z Jin
  • Antivir Res
  • 2017
VIEW 1 EXCERPT

The discovery of IDX21437: design, synthesis and antiviral evaluation of 20-a-chloro-20-b-Cmethyl branched uridine pronucleotides as potent livertargeted HCV polymerase inhibitors

Alexandre F-R
  • Bioorg Med Chem Lett
  • 2017
VIEW 1 EXCERPT

The protide prodrug technology: from the concept to the clinic

Y Mehellou
  • J Med Chem. Epub ahead of print
  • 2017

Nucleotide derivatives which are HCV inhibitors for use in the treatment of hepatitis

G Kalayanov
  • C. September
  • 2016